GLAUCOMA 32 EWAP JUNE 2022 Having the connection between seeing and understanding the concept so they know how to treat what’s going on in the eye is important, she said. “I review the Basic and Clinical Science Course Glaucoma textbook from the American Academy of Ophthalmology with the first-year classes, and I always tell them to look at the pathway and [understand] the anatomy and pathophysiology behind the specific disease. Now, using OcuSim, they can immerse themselves and go into the eye, into the angle, and understand why patients have glaucoma,” Dr. Chaku said. MIGS is an exciting space, she added, and it’s important to understand why we’re in the angle and why we’re getting lower pressures with new devices and treatments. “It gives them that concept clarity on why to choose specific treatments for different patients. “It puts things together in a different way that we haven’t been able to do before,” Dr. Chaku said. Dr. Khanna added that at Loyola, the simulation training is embedded into the curriculum. Dr. Khanna said that she often finds herself learning from trainees about the technology, and students are eager to continue on past individual modules that they’re working on. This teaching option incorporates visual, tactical, and audio learning. “As I’m creating it, I’m learning what these VR headsets are capable of and slowly introducing more interactivity,” Dr. Khanna said. “The more we do it, the more the residents use it, the more ideas come up.” The main limiting factor is money, she added. Dr. Khanna said she does not have information on the specific procedures, like MIGS, in her lessons yet but she would be open to working with companies in the future. “Their product, they know best, and how to teach the residents, the educators know best, so we can merge the two worlds,” she said. Dr. Khanna noted that there are many potential applications for her technology in the future as new procedures are developed. She thinks it could be valuable not just to trainees but also for those trying to keep their skills fresh. She has plans to develop a retina module as well. The way she has designed the simulation is as if the participants are in a virtual study room, with the ability to teleport themselves into different parts of the room and look at the eye from different angles. In the future, she intends for them to be able to transport to different subspecialties and to the clinic. With the advent of MIGS, the secondary effect is people are paying more attention to the angle, and from an educational standpoint, that has exploded the learning curve in that space, Dr. Chaku said. “The reason I was so excited about OcuSim is because [it] gives a higher level of understanding and clarity to the residents that you can’t always draw out from a book,” she said. Dr. Chaku added that this makes a difference because many people think that glaucoma is all about the pressure. But glaucoma is trying to figure out the right diagnosis and why we’re instituting this therapy, what’s the next step, and why will it work in this patient. “If you don’t understand that from a basic science/ anatomy level, you’ll never give the patient the full treatment value,” she said. In the future, Dr. Khanna hopes to expand the technology even more. For example, she said the next phase is to be able to incorporate individual case presentations. Dr. Chaku added that since there are different training modules in glaucoma, it will be helpful to gives trainees different scenarios that they can examine in OcuSim and understand what’s happening and determine treatment plans. “We’ve been so excited about this technology,” she said. “We’re such a high-tech field and pushing the education envelope is exciting, and it allows us to do the best we can to get the next generation trained.” EWAP Editors’ note: Dr. Chaku is Glaucoma Service Director, Loyola University Medical Center, Maywood, Illinois, and declared no relevant financial interests. Dr. Khanna is Vice Chairperson of Education, Department of Ophthalmology, Loyola University, Chicago, Illinois, and has interests with OcuSim. ADVERTISER LISTING Alcon Page 5 www.alcon.com Johnson and Johnson Vision Page 2 www.jjvision.com Feather Page 23 www.feather.co.jp/en/ Oculus Page 19 www.cornealbiomechanics.com APACRS Page 6, 35, 36 www.apacrs.org
RkJQdWJsaXNoZXIy Njk2NTg0